Mitomycins
- Generic Name
- Mitomycins
- Brand Names
- Jelmyto, Mitosol, Mutamycin
- Drug Type
- Small Molecule
- Chemical Formula
- C15H18N4O5
- CAS Number
- 50-07-7
- Unique Ingredient Identifier
- 50SG953SK6
- Background
Mitomycin is an antineoplastic antibiotic first isolated by Japanese microbiologists in the 1950s from cultures of Streptomyces caespitosus. It is an alkylating agent that inhibits DNA synthesis (and, at higher concentrations, RNA and protein synthesis) by cross-linking the complementary strands of the DNA double helix. Few other antibiotics have been discov...
- Indication
For treatment of malignant neoplasm of lip, oral cavity, pharynx, digestive organs, peritoneum, female breast, and urinary bladder. Also used as an adjunct to ab externo glaucoma surgery. Mitomycin is also indicated as a pyelocalyceal solution for the treatment of adults with low-grade upper tract urothelial cancer (LG-UTUC).
- Associated Conditions
- Anal Cancer, Bladder Cancer, Breast Cancer, Carcinoma of the Head and Neck, Cervical Cancer, Gastric Adenocarcinoma, Mesothelioma, Non-Small Cell Lung Cancer (NSCLC), Pancreatic Adenocarcinoma, Ab externo surgery Glaucoma, Low-grade Upper Tract Urothelial Cancer (LG-UTUC)
- Associated Therapies
- -
Radiation Therapy and Chemotherapy in Treating Patients With Head and Neck Cancer
- Conditions
- First Posted Date
- 2004-08-10
- Last Posted Date
- 2013-07-25
- Lead Sponsor
- Yale University
- Registration Number
- NCT00002507
- Locations
- 🇺🇸
Yale Comprehensive Cancer Center, New Haven, Connecticut, United States
Fluorouracil With or Without Mitomycin in Treating Patients With Peritoneal Cancer
- First Posted Date
- 2004-05-04
- Last Posted Date
- 2011-04-26
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Registration Number
- NCT00006112
- Locations
- 🇫🇷
Institut Gustave Roussy, Villejuif, France
Nitrocamptothecin Compared With Other Chemotherapy in Treating Patients With Recurrent or Refractory Cancer of the Pancreas
- Conditions
- First Posted Date
- 2004-04-26
- Last Posted Date
- 2013-12-04
- Lead Sponsor
- Astex Pharmaceuticals, Inc.
- Registration Number
- NCT00005870
- Locations
- 🇺🇸
SuperGen, Incorporated, San Ramon, California, United States
🇺🇸Roswell Park Cancer Institute, Buffalo, New York, United States
S9700 Combination Chemotherapy in Treating Patients With Stage II or Stage III Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2004-04-22
- Last Posted Date
- 2013-01-03
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 54
- Registration Number
- NCT00003018
- Locations
- 🇺🇸
MBCCOP - University of South Alabama, Mobile, Alabama, United States
🇺🇸Loyola University Medical Center, Maywood, Illinois, United States
🇺🇸USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
Radiation Therapy With or Without Chemotherapy After Surgery in Treating Patients With Stage IB or Stage IIA Cervical Cancer
- Conditions
- First Posted Date
- 2004-04-14
- Last Posted Date
- 2012-07-11
- Target Recruit Count
- 700
- Registration Number
- NCT00003209
- Locations
- 🇬🇧
Derbyshire Royal Infirmary, Derby, England, United Kingdom
🇬🇧Beatson Oncology Centre, Glasgow, Scotland, United Kingdom
Irinotecan Plus Mitomycin in Treating Patients With Advanced Solid Tumors
- Conditions
- First Posted Date
- 2004-04-09
- Last Posted Date
- 2012-08-09
- Target Recruit Count
- 12
- Registration Number
- NCT00003710
- Locations
- 🇺🇸
San Antonio Cancer Institute, San Antonio, Texas, United States
Second-look Surgery With or Without Intraperitoneal Chemotherapy in Treating Patients With Recurrent Colorectal Cancer
- Conditions
- First Posted Date
- 2004-03-24
- Last Posted Date
- 2021-02-17
- Lead Sponsor
- UNICANCER
- Registration Number
- NCT00005944
- Locations
- 🇫🇷
CHR de Besancon - Hopital Jean Minjoz, Besancon, France
🇫🇷Institut Bergonie, Bordeaux, France
🇫🇷Centre Hospitalier Universitaire de Dijon, Dijon, France
Standard Therapy Given With or Without Combination Chemotherapy in Treating Patients With Non-small Cell Lung Cancer
- Conditions
- First Posted Date
- 2004-02-20
- Last Posted Date
- 2013-12-18
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 1800
- Registration Number
- NCT00003240
- Locations
- 🇬🇧
Middlesex Hospital- Meyerstein Institute, London, England, United Kingdom
Active Symptom Control With or Without Chemotherapy in Treating Patients With Malignant Pleural Mesothelioma
- Conditions
- First Posted Date
- 2004-01-13
- Last Posted Date
- 2013-08-07
- Lead Sponsor
- Medical Research Council
- Target Recruit Count
- 840
- Registration Number
- NCT00075699
- Locations
- 🇬🇧
Royal Marsden NHS Foundation Trust - Surrey, Sutton, England, United Kingdom
🇬🇧Leeds General Infirmary at Leeds Teaching Hospital NHS Trust, Leeds, England, United Kingdom
🇬🇧Saint Bartholomew's Hospital, London, England, United Kingdom
Chemoembolization in Treating Patients With Primary Liver Cancer or Metastases to the Liver
- Conditions
- Interventions
- First Posted Date
- 2003-10-09
- Last Posted Date
- 2023-07-05
- Lead Sponsor
- Eastern Cooperative Oncology Group
- Target Recruit Count
- 50
- Registration Number
- NCT00003907
- Locations
- 🇺🇸
Rush-Copley Cancer Care Center, Aurora, Illinois, United States
🇺🇸Veterans Affairs Medical Center - Atlanta (Decatur), Decatur, Georgia, United States
🇺🇸Borgess Medical Center, Kalamazoo, Michigan, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.